Scalper1 News
Drugmaker Baxalta (BXLT) was trading up Monday, against a tide of broad stock market declines, as it inked an immuno-oncology deal and was rumored to be close to a sale to Shire (SHPG). Baxalta said that it had agreed to pay privately held Symphogen $175 million upfront for option rights to six therapies that Symphogen is developing, which target checkpoints in cancer cells that inhibit the immune system’s ability to fight them. The principle of Scalper1 News
Scalper1 News